![]() ![]() During March 6, 2022–May 21, 2022, the number of oral antivirals dispensed per 100,000 population increased from 3.3 to 77.4 in low-, from 4.5 to 70.0 in medium-, and from 7.8 to 35.7 in high-vulnerability zip codes. Most (70.3%) oral antivirals were dispensed during March 7–May 21, 2022. residents live in low-, 31% in medium-, and 49% in high-social vulnerability zip codes. Zip codes represented areas classified as low, medium, or high social vulnerability approximately 20% of U.S. § Data from December 23, 2021–May 21, 2022, were analyzed to describe oral antiviral prescription dispensing overall and by week, stratified by zip code social vulnerability. ![]() Beginning March 7, 2022, a series of strategies was implemented to expand COVID-19 oral antiviral access, including the launch of the Test to Treat initiative. Department of Health and Human Services (HHS) on December 23, 2021. These medications received Emergency Use Authorization from the Food and Drug Administration (FDA) in December 2021 † and were made available at no cost to recipients through the U.S. Molnupiravir (Lagevrio) and nirmatrelvir/ritonavir (Paxlovid) are oral antiviral agents effective at preventing hospitalization and death in patients with mild to moderate COVID-19 who are at high risk* for progression to severe COVID-19 when initiated within 5 days of symptom onset. Ensuring equitable access to effective COVID-19 therapies is essential to reducing health disparities. The COVID-19 pandemic has highlighted and exacerbated long-standing inequities in the social determinants of health ( 1– 3).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |